ADARx Pharmaceuticals, Inc.

Exhibit 99.1 ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates - Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 - - Advanced three Phase 2 clinical trials for agazisiran for the treatment of complement-mediated diseases - - Received Fast Track designation for onvuzosiran for HAE - SAN DIEGO, Calif., November 12, 202…

8-K · 2026-11-12 · 0001193125-26-458321

Focused on Developing Next-Generation siRNA Therapeutics Designed to Treat Broad Spectrum of Diseases November 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation, other than statements of historical facts, are forward-looking statements, including statements regarding our expected cash runway; the potential benefits, effectiveness and safety of our produc…

8-K · 2026-11-12 · 0001193125-26-458321

EX-10.7 7 d903461dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 ADAR X P HARMACEUTICALS, I NC. N ON -E MPLOYEE D IRECTOR C OMPENSATION P OLICY Each member of the Board of Directors (the “Board”) of ADARx Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or…

S-1/A · 2026-09-21 · 0001193125-26-396007

EX-4.1 2 d903461dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 INCORPORATED UNDER THE CUSIP XXXXXX XX X LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: COUNTERSIGNED is the record holder of AND EQUINITI FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF ADARX PHARMACEUTICALS, INC. TRUST transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly…

S-1/A · 2026-09-14 · 0001193125-26-390724

EX-4.2 6 d903461dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 2nd day of August, 2023, by and among ADARx Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, certain of the Investors (the “Existing I…

S-1 · 2026-09-04 · 0001193125-26-383838